World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016

Journal of Translational Medicine

Meeting Report

Francesco M. Marincola¹  Giuseppe Masucci²  Carlo Bifulco³  Jerome Galon⁴  Alessandro Lugli⁵  Franck Pages⁶  Paolo A. Ascierto⁷ 

[1] AbbVie Medical Corporation, Redwood City, CA, USA;Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden;Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR, USA;INSERM (National Institute of Health and Medical Research), Paris, France;Institute of Pathology, University of Bern, Bern, Switzerland;Laboratory of Immunology, Hopital Européen Georges Pompidou, Paris, France;Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori “Fondazione G. Pascale”, Via Mariano Semmola, 80131, Naples, Italy;

关键词: Immunoscore;    Lean management system;    Cumulative “Suppression Index”;   

DOI  :  10.1186/s12967-017-1310-9

 received in 2017-08-04, accepted in 2017-09-28,  发布年份 2017

来源: Springer

【 摘 要 】

The predictive accuracy of the traditional staging system is based on disease progression as a tumour cell-autonomous process, but it fails to incorporate the effects of the host immune response. A precise analysis of the immune component of the tumour microenvironment by computer-based analysis may be essential to managing patients better, opening the road to an expertise in this new emerging field. The Immunoscore as a new possible approach in the classification of cancer, designated TNM-Immune, studied in colon cancer patients with predictive and prognostic value. This new scoring system is derived from the immune contexture, and is based on the numeration of lymphocyte populations, both in the core of the tumour and in the invasive margin of tumours. The Immunoscore demonstrated to be quantitative, reproducible and robust. The usefulness of Immunoscore in advanced melanoma cancer patients has been as well demonstrated; the correlation of marker expression profile with clinical outcome is ongoing. More recently, the Immunoscore could be a useful prognostic marker in patients with rectal cancer treated by primary surgery. A multivariable Cumulative “Suppression Index” scoring system has been also studied in Oral Squamous Cell Carcinoma patients: it evaluates both the tumor and stromal microcompartments at the invasive margin and summarizes them into the score, providing an accurate stratification, independent of stage, tumour classification. The introduction of Immunoscore requires a redefinition of the Laboratory system according to the LEAN Management process, which has been already implemented in referral research labs. The definition and test of hundreds of biomarkers, in the tumour contexture represents a definitive scientific progression. However, there is still a need of substantial body of work to reach the end of the tunnel to assure a personalize treatment.

【 授权许可】

CC BY   
© The Author(s) 2017